Clinical efficacy and molecular response correlates of the Wee1 inhibitor adavosertib with cisplatin in metastatic triple-negative breast cancer (mTNBC)

Keenan T., Li T., Vallius T., Guerriero J.L., Tayob N., Kochupurakkal B., Davis J., Pastorello R., Tahara R.K., Anderson L., Conway J., He M.X., Shannon E., Godin R.E., Sorger P.K., D’Andrea A., Overmoyer B., Winer E.P., Mittendorf E.A., Van Allen E.*, Shapiro G.I.*, Tolaney S.M.*

Manuscript in preparation

Available images

cis.jpg
Clinical Benefit - Cisplatin Biopsy

CyCIF image of a biopsy from a patient with triple-negative breast cancer (TNBC) liver metastasis. This biopsy was obtained after the first infusion of Cisplatin (Cis) chemotherapy, before Wee1 inhibitor therapy.

CyCIF image
Wee1.jpg
Clinical Benefit - Cis Wee1i Biopsy

CyCIF image of a biopsy from a patient with triple-negative breast cancer (TNBC) liver metastasis, after combination therapy with Cisplatin and the Wee1 inhibitor Adavosertib.

CyCIF image
25_C1_a.jpg
No Clinical Benefit - Cisplatin Biopsy

CyCIF image of a biopsy from a patient with triple-negative breast cancer (TNBC) liver metastasis. This biopsy was obtained after the first infusion of Cisplatin (Cis) chemotherapy, before Wee1 inhibitor therapy.

CyCIF image
25_C2_b.jpg
No Clinical Benefit - Cis Wee1i Biopsy

CyCIF image of a biopsy from a patient with triple-negative breast cancer (TNBC) liver metastasis, after combination therapy with Cisplatin and the Wee1 inhibitor Adavosertib.

CyCIF image